Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

BLADDER CANCER

Antibiotics impair immunotherapy for urothelial cancer

Nature Reviews Urology volume 17, pages 605–606 (2020)Cite this article

Subjects

Pooled clinical trial data reveal that antibiotics worsen progression-free survival and overall survival in patients with locally advanced and metastatic urothelial cancer receiving anti-PDL1 therapy. Consensus guidelines for antibiotic use in these patients, as well as diagnostic tools and corrective measures, are needed to decrease primary resistance to immune checkpoint inhibitors.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Antibiotic use in patients receiving immune checkpoint inhibitors.

References

  1. Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91–97 (2018).

    Article  CAS  PubMed  Google Scholar 

  2. Hopkins, A. M., Kichenadasse, G., Karapetis, C. S., Rowland, A. & Sorich, M. J. Concomitant antibiotic use and survival in urothelial carcinoma treated with atezolizumab. Eur. Urol. https://doi.org/10.1016/j.eururo.2020.06.061 (2020).

    Article  PubMed  Google Scholar 

  3. Pinato, D. J. et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 5, 1774–1778 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  4. Derosa, L. et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann. Oncol. 29, 1437–1444 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Mohiuddin, J. J. et al. Association of antibiotic exposure with survival and toxicity in patients with melanoma receiving immunotherapy. J. Natl Cancer Inst. https://doi.org/10.1093/jnci/djaa057 (2020).

    Article  PubMed Central  Google Scholar 

  6. Vétizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079–1084 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Derosa, L. et al. Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients. Eur. Urol. 78, 195–206 (2020).

    Article  CAS  PubMed  Google Scholar 

  8. Uribe-Herranz, M. et al. Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response. J. Clin. Invest. 130, 466–479 (2020).

    Article  CAS  PubMed  Google Scholar 

  9. Uribe-Herranz, M. et al. Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12. JCI Insight 3, e94952 (2018).

    Article  PubMed Central  Google Scholar 

  10. Youngster, I. et al. 90. Fecal microbiota transplantation in metastatic melanoma patients resistant to anti-PD-1 treatment. Open Forum Infect. Dis. 6 (Suppl. 2), 7 (2019).

    Article  Google Scholar 

Download references

Acknowledgements

L.Z. is supported by the Ligue contre le Cancer (équipe labellisée); Agence Nationale de la Recherche (ANR) – Projets blancs; Association pour la recherche sur le cancer (ARC) SIGN’IN; Cancéropôle Ile-de-France; Fondation pour la Recherche Médicale (FRM); a donation by Elior; Gustave Roussy Odyssea, the European Union Horizon 2020 Project Oncobiome; Fondation Carrefour; Institut National du Cancer (INCa); INSERM; Institut Universitaire de France; LabEx Immuno-Oncology (grant ANR-18-IDEX-0001); Recherche Hospitalo-Universitaire (RHU) Torino Lumière; the Seerave Foundation; and Site de Recherche Intégrée sur le Cancer (SIRIC) Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE).

Author information

Authors and Affiliations

  1. Gustave Roussy Cancer Center, Villejuif, France

    Lisa Derosa & Laurence Zitvogel

  2. Université Paris Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France

    Lisa Derosa & Laurence Zitvogel

  3. INSERM U1015, Villejuif, France

    Lisa Derosa & Laurence Zitvogel

Authors
  1. Lisa Derosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laurence Zitvogel
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

L.D. researched data for the article, contributed substantially to discussions of the content and wrote the initial draft. L.D. and L.Z. reviewed and/or edited the manuscript before submission.

Corresponding author

Correspondence to Laurence Zitvogel.

Ethics declarations

Competing interests

L.Z. declares that she is a founder of everImmune and conducts research projects for Kaleido, Innovate Pharma and Transgene. L.D. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Derosa, L., Zitvogel, L. Antibiotics impair immunotherapy for urothelial cancer. Nat Rev Urol 17, 605–606 (2020). https://doi.org/10.1038/s41585-020-0373-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-020-0373-1

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing